The current financial score of Enveric Biosciences Inc is 7.47. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Enveric Biosciences Inc is 9.43. Its current P/E ratio is -0.07, which is -96.90% below the recent high of -0.00 and -612.56% above the recent low of -0.48.
No earnings forecast score is currently available for Enveric Biosciences Inc. The Biotechnology & Medical Research industry's average is 8.11. The average price target is 120.00, with a high of 120.00 and a low of 120.00.
The current price momentum score of Enveric Biosciences Inc is 5.36. Currently, the stock price is trading between the resistance level at 1.74 and the support level at 1.26, making it suitable for range-bound swing trading.
The current institutional shareholding score of Enveric Biosciences Inc is 3.00. The latest institutional shareholding proportion is 6.01%, representing a quarter-over-quarter increase of 27.81%.
The current risk assessment score of Enveric Biosciences Inc is 2.36. The company's beta value is 1.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.